Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease

ACS Chemical Neuroscience

Volumn 7, Issue 4, 2016, Pages 454-463

  Woodling, Nathaniel S ^a,b   Andreasson, Katrin I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; and EP4 receptor; cyclooxgenases; EP2 receptor; EP3 receptor; microglia; neuroinflammation; prostaglandin E2

Indexed keywords

AMYLOID BETA PROTEIN; G PROTEIN COUPLED RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROSTAGLANDIN F2 ALPHA;

ALZHEIMER DISEASE; COMPLEX FORMATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MICROGLIA; MOLECULAR BIOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; DRUG EFFECTS; ENCEPHALITIS; GENETICS; METABOLISM; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; DINOPROST; ENCEPHALITIS; HUMANS; MICROGLIA; SIGNAL TRANSDUCTION;

EID: 84966309395     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.6b00016     Document Type: Review

References (100)

1. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., and Evans, D. A. (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 60, 1119-1122 10.1001/archneur.60.8.1119
2. Alzheimer, A. (1907) Über eine eigenartige Erkrankung der Hirnrinde [About a peculiar disease of the cerebral cortex] Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146-148
3. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120, 885-890 10.1016/S0006-291X(84)80190-4
4. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology Proc. Natl. Acad. Sci. U. S. A. 83, 4913-4917 10.1073/pnas.83.13.4913
5. Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., and James, L. et al. 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 349, 704-706 10.1038/349704a0
6. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., Da Silva, H. A., Haines, J. L., Perkicak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St George-Hyslop, P. H. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 375, 754-760 10.1038/375754a0
7. Hardy, J. A. and Higgins, G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis Science 256, 184-185 10.1126/science.1566067
8. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Björnsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., and Stefansson, K. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline Nature 488, 96-99 10.1038/nature11283
9. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42, 631-631 10.1212/WNL.42.3.631
10. Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., and Berg, L. (1996) Cerebral amyloid deposition and diffuse plaques in normal aging: Evidence for presymptomatic and very mild Alzheimer's disease Neurology 46, 707-719 10.1212/WNL.46.3.707
11. Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A. M., Benzinger, T. L. S., and Morris, J. C. (2011) Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data Ann. Neurol. 70, 857-861 10.1002/ana.22608
12. Palop, J. J. and Mucke, L. (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks Nat. Neurosci. 13, 812-818 10.1038/nn.2583
13. Wisniewski, T. and Konietzko, U. (2008) Amyloid-beta immunisation for Alzheimer's disease Lancet Neurol. 7, 805-811 10.1016/S1474-4422(08)70170-4
14. Miller, G. (2012) Alzheimer's research. Stopping Alzheimer's before it starts Science 337, 790-792 10.1126/science.337.6096.790
15. Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., and Andreasson, K. I. (2015) Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease Trends Neurosci. 38, 621-636 10.1016/j.tins.2015.08.006
16. Akiyama, H. H., Barger, S. S., Barnum, S. S., Bradt, B. B., Bauer, J. J., Cole, G. M. G., Cooper, N. R. N., Eikelenboom, P. P., Emmerling, M. M., Fiebich, B. L. B., Finch, C. E. C., Frautschy, S. S., Griffin, W. S. W., Hampel, H. H., Hull, M. M., Landreth, G. G., Lue, L. L., Mrak, R. R., Mackenzie, I. R. I., McGeer, P. L. P., O'Banion, M. K. M., Pachter, J. J., Pasinetti, G. G., Plata-Salaman, C. C., Rogers, J. J., Rydel, R. R., Shen, Y. Y., Streit, W. W., Strohmeyer, R. R., Tooyoma, I. I., Van Muiswinkel, F. L. F., Veerhuis, R. R., Walker, D. D., Webster, S. S., Wegrzyniak, B. B., Wenk, G. G., and Wyss-Coray, T. T. (2000) Inflammation and Alzheimer's disease Neurobiol. Aging 21, 383-421 10.1016/S0197-4580(00)00124-X
17. Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C. A., Breitner, J. C., Cole, G. M., Golenbock, D. T., and Kummer, M. P. (2015) Neuroinflammation in Alzheimer's disease Lancet Neurol. 14, 388-405 10.1016/S1474-4422(15)70016-5
18. El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., Freeman, M. W., and Luster, A. D. (2003) CD36 mediates the innate host response to beta-amyloid J. Exp. Med. 197, 1657-1666 10.1084/jem.20021546
19. Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., and Golenbock, D. T. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta Nat. Immunol. 9, 857-865 10.1038/ni.1636
20. Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., and Landreth, G. E. (2009) CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar A -Stimulated Microglial Activation J. Neurosci. 29, 11982-11992 10.1523/JNEUROSCI.3158-09.2009
21. Woodling, N. S., Wang, Q., Priyam, P. G., Larkin, P., Shi, J., Johansson, J. U., Zagol-Ikapitte, I., Boutaud, O., and Andreasson, K. I. (2014) Suppression of Alzheimer-Associated Inflammation by Microglial Prostaglandin-E2 EP4 Receptor Signaling J. Neurosci. 34, 5882-5894 10.1523/JNEUROSCI.0410-14.2014
22. Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P., and Gauthier, S. (1993) Apolipoprotein E polymorphism and Alzheimer's disease Lancet 342, 697-699 10.1016/0140-6736(93)91705-Q
23. Li, X., Montine, K. S., Keene, C. D., and Montine, T. J. (2015) Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia FASEB J. 29, 1754-1762 10.1096/fj.14-262683
24. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.-C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George Hyslop, P., Singleton, A., and Hardy, J. (2013) TREM2Variants in Alzheimer's Disease N. Engl. J. Med. 368, 117 10.1056/NEJMoa1211851
25. Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., and Lamb, B. T. (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models J. Exp. Med. 212, 287-295 10.1084/jem.20142322
26. Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., and Young, K. L. et al. 2015, TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer's Disease Model Cell 160, 1061 10.1016/j.cell.2015.01.049
27. Mcgeer, P. L. and McGeer, E. G. (2007) NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies Neurobiol. Aging 28, 639-647 10.1016/j.neurobiolaging.2006.03.013
28. Wyss-Coray, T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015 10.1038/nm1484
29. Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-Caballero, M., Holscher, C., Perry, V. H., and Gomez-Nicola, D. (2016) Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology Brain 139, 891 10.1093/brain/awv379
30. Fonseca, M. I., Zhou, J., Botto, M., and Tenner, A. J. (2004) Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease J. Neurosci. 24, 6457-6465 10.1523/JNEUROSCI.0901-04.2004
31. Arancio, O., Zhang, H. P., Chen, X., Lin, C., Trinchese, F., Puzzo, D., Liu, S., Hegde, A., Yan, S. F., Stern, A., Luddy, J. S., Lue, L.-F., Walker, D. G., Roher, A., Buttini, M., Mucke, L., Li, W., Schmidt, A. M., Kindy, M., Hyslop, P. A., Stern, D. M., and Du Yan, S. S. (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice EMBO J. 23, 4096-4105 10.1038/sj.emboj.7600415
32. Wyss-Coray, T., Yan, F., Lin, A., Lambris, J., Alexander, J., Quigg, R., and Masliah, E. (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice Proc. Natl. Acad. Sci. U. S. A. 99, 10837-10842 10.1073/pnas.162350199
33. Wyss-Coray, T., Lin, C., Yan, F., Yu, G. Q., Rohde, M., McConlogue, L., Masliah, E., and Mucke, L. (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice Nat. Med. 7, 612-618 10.1038/87945
34. Mizutani, M., Pino, P. A., Saederup, N., Charo, I. F., Ransohoff, R. M., and Cardona, A. E. (2012) The Fractalkine Receptor but Not CCR2 Is Present on Microglia from Embryonic Development throughout Adulthood J. Immunol. 188, 29-36 10.4049/jimmunol.1100421
35. El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., and Luster, A. D. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease Nat. Med. 13, 432-438 10.1038/nm1555
36. Colton, C. A. (2009) Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain J. Neuroimmune Pharmacol 4, 399-418 10.1007/s11481-009-9164-4
37. Hickman, S. E., Allison, E. K., and El Khoury, J. (2008) Microglial Dysfunction and Defective Beta-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice J. Neurosci. 28, 8354-8360 10.1523/JNEUROSCI.0616-08.2008
38. McGeer, P. L., McGeer, E., Rogers, J., and Sibley, J. (1990) Anti-inflammatory drugs and Alzheimer disease Lancet 335, 1037 10.1016/0140-6736(90)91101-F
39. McGeer, P. L., Schulzer, M., and McGeer, E. G. (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies Neurology 47, 425-432 10.1212/WNL.47.2.425
40. Stewart, W. F., Kawas, C., Corrada, M., and Metter, E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use Neurology 48, 626-632 10.1212/WNL.48.3.626
41. Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K., Mayer, L., and Breitner, J. (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study Neurology 59, 880-886 10.1212/WNL.59.6.880
42. in t Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M., and Stricker, B. H. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N. Engl. J. Med. 345, 1515-1521 10.1056/NEJMoa010178
43. Vlad, S. C., Miller, D. R., Kowall, N. W., and Felson, D. T. (2008) Protective effects of NSAIDs on the development of Alzheimer disease Neurology 70, 1672-1677 10.1212/01.wnl.0000311269.57716.63
44. Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C., Lyketsos, C. G., Breitner, J. C. S., Welsh-Bohmer, K. A., and the Cache County Investigators (2007) Does NSAID use modify cognitive trajectories in the elderly? The Cache County study Neurology 69, 275-282 10.1212/01.wnl.0000265223.25679.2a
45. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., and Kogan, F. (1993) Clinical trial of indomethacin in Alzheimer's disease Neurology 43, 1609-1611 10.1212/WNL.43.8.1609
46. Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., and the Alzheimer's Disease Cooperative Study (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA, J. Am. Med. Assoc. 289, 2819-2826 10.1001/jama.289.21.2819
47. Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., Baranak, C. C., and the Rofecoxib Protocol 091 Study Group (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62, 66-71 10.1212/WNL.62.1.66
48. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., Baron, J. A., and the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N. Engl. J. Med. 352, 1092-1102 10.1056/NEJMoa050493
49. ADAPT Research Group, Martin, B. K., Szekely, C., Brandt, J., Piantadosi, S., Breitner, J. C. S., Craft, S., Evans, D., Green, R., and Mullan, M. (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch. Neurol. 65, 896-905 10.1001/archneur.2008.65.7.nct70006
50. Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. E., Green, R. C., Ismail, M. S., Martin, B. K., Mullan, M. J., Sabbagh, M., Tariot, P. N., and ADAPT Research Group (2011) Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimer's Dementia 7, 402-411 10.1016/j.jalz.2010.12.014
51. Sonnen, J. A., Montine, K. S., Quinn, J. F., Kaye, J. A., Breitner, J. C., and Montine, T. J. (2008) Biomarkers for cognitive impairment and dementia in elderly people Lancet Neurol. 7, 704-714 10.1016/S1474-4422(08)70162-5
52. ADAPT Research Group (2013) Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) Alzheimer's Dementia 9, 714-723 10.1016/j.jalz.2012.11.012
53. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414, 212-216 10.1038/35102591
54. Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., van Leuven, F., and Landreth, G. E. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice Brain 128, 1442-1453 10.1093/brain/awh452
55. Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., and Cole, G. M. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease J. Neurosci. 20, 5709-5714
56. Wilkinson, B. L., Cramer, P. E., Varvel, N. H., Reed-Geaghan, E., Jiang, Q., Szabo, A., Herrup, K., Lamb, B. T., and Landreth, G. E. (2012) Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease Neurobiol. Aging 33, 197.e121-197.e32 10.1016/j.neurobiolaging.2010.06.014
57. Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., and Landreth, G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease J. Neurosci. 23, 7504-7509
58. Czirr, E., Leuchtenberger, S., Dorner-Ciossek, C., Schneider, A., Jucker, M., Koo, E. H., Pietrzik, C. U., Baumann, K., and Weggen, S. (2007) Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations J. Biol. Chem. 282, 24504-24513 10.1074/jbc.M700618200
59. Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H.-U., Bulic, B., Schneider-Axmann, T., Bayer, T. A., Weggen, S., and Wirths, O. (2012) No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease Neurobiol. Aging 33, 833.e39-833.e50 10.1016/j.neurobiolaging.2011.08.006
60. Kotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi, A., Lesne, S., Falinska, A., Younkin, L. H., Younkin, S. G., Rowan, M., Cleary, J., Wallis, R. A., Sun, G. Y., Cole, G., Frautschy, S., Anwyl, R., and Ashe, K. H. (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity Brain 131, 651-664 10.1093/brain/awn008
61. Varvel, N. H., Bhaskar, K., Kounnas, M. Z., Wagner, S. L., Yang, Y., Lamb, B. T., and Herrup, K. (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease J. Clin. Invest. 119, 3692-3702 10.1172/JCI39716
62. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J., and the VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N. Engl. J. Med. 343, 1520-1528 10.1056/NEJM200011233432103
63. Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M., and Fitzgerald, G. A. (2004) COX-2-derived prostacyclin confers atheroprotection on female mice Science 306, 1954-1957 10.1126/science.1103333
64. Fitzgerald, G. A. (2004) Coxibs and cardiovascular disease N. Engl. J. Med. 351, 1709-1711 10.1056/NEJMp048288
65. Montine, T. J. T., Sidell, K. R. K., Crews, B. C. B., Markesbery, W. R. W., Marnett, L. J. L., Roberts, L. J. L., and Morrow, J. D. J. (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD Neurology 53, 1495-1498 10.1212/WNL.53.7.1495
66. Combrinck, M., Williams, J., De Berardinis, M. A., Warden, D., Puopolo, M., Smith, A. D., and Minghetti, L. (2006) Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease J. Neurol., Neurosurg. Psychiatry 77, 85-88 10.1136/jnnp.2005.063131
67. Breyer, R. M., Bagdassarian, C. K., Myers, S. A., and Breyer, M. D. (2001) Prostanoid receptors: subtypes and signaling Annu. Rev. Pharmacol. Toxicol. 41, 661-690 10.1146/annurev.pharmtox.41.1.661
68. Andreasson, K. (2010) Emerging roles of PGE2 receptors in models of neurological disease Prostaglandins Other Lipid Mediators 91, 104-112 10.1016/j.prostaglandins.2009.04.003
69. Johansson, J., Woodling, N., Shi, J., and Andreasson, K. (2015) Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease Current Immunology Reviews 11, 125-131 10.2174/1573395511666150707181414
70. Carrasco, E. E., Casper, D. D., and Werner, P. P. (2007) PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity J. Neurosci. Res. 85, 3109-3117 10.1002/jnr.21425
71. Zhen, G., Kim, Y. T., Li, R.-C., Yocum, J., Kapoor, N., Langer, J., Dobrowolski, P., Maruyama, T., Narumiya, S., and Doré, S. (2012) PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease Neurobiol. Aging 33, 2215-2219 10.1016/j.neurobiolaging.2011.09.017
72. Liang, X., Wang, Q., Hand, T., Wu, L., Breyer, R. M., Montine, T. J., and Andreasson, K. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease J. Neurosci. 25, 10180-10187 10.1523/JNEUROSCI.3591-05.2005
73. Tamagno, E. E., Bardini, P. P., Obbili, A. A., Vitali, A. A., Borghi, R. R., Zaccheo, D. D., Pronzato, M. A. M., Danni, O. O., Smith, M. A. M., Perry, G. G., and Tabaton, M. M. (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons Neurobiol. Dis. 10, 279-288 10.1006/nbdi.2002.0515
74. Montine, T. J., Milatovic, D., Gupta, R. C., Valyi-Nagy, T., Morrow, J. D., and Breyer, R. M. (2002) Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent J. Neurochem. 83, 463-470 10.1046/j.1471-4159.2002.01157.x
75. Shie, F.-S., Montine, K. S., Breyer, R. M., and Montine, T. J. (2005) Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity Glia 52, 70-77 10.1002/glia.20220
76. Shie, F.-S., Breyer, R. M., and Montine, T. J. (2005) Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity Am. J. Pathol. 166, 1163-1172 10.1016/S0002-9440(10)62336-X
77. Keene, C. D., Chang, R. C., Lopez-Yglesias, A. H., Shalloway, B. R., Sokal, I., Li, X., Reed, P. J., Keene, L. M., Montine, K. S., Breyer, R. M., Rockhill, J. K., and Montine, T. J. (2010) Suppressed Accumulation of Cerebral Amyloid {beta} Peptides in Aged Transgenic Alzheimer's Disease Mice by Transplantation with Wild-Type or Prostaglandin E2 Receptor Subtype 2-Null Bone Marrow Am. J. Pathol. 177, 346 10.2353/ajpath.2010.090840
78. Li, X., Melief, E., Postupna, N., Montine, K. S., Keene, C. D., and Montine, T. J. (2015) Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis Am. J. Pathol. 185, 230-239 10.1016/j.ajpath.2014.09.016
79. Johansson, J. U., Pradhan, S., Lokteva, L. A., Woodling, N. S., Ko, N., Brown, H. D., Wang, Q., Loh, C., Cekanaviciute, E., Buckwalter, M., Manning-Boǧ, A. B., and Andreasson, K. I. (2013) Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia J. Neurosci. 33, 16016-16032 10.1523/JNEUROSCI.2203-13.2013
80. Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., and Andreasson, K. I. (2015) Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models J. Clin. Invest. 125, 350-364 10.1172/JCI77487
81. Shi, J., Wang, Q., Johansson, J. U., Liang, X., Woodling, N. S., Priyam, P., Loui, T. M., Merchant, M., Breyer, R. M., Montine, T. J., and Andreasson, K. (2012) Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease Ann. Neurol. 72, 788-798 10.1002/ana.23677
82. 2 receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia J. Clin. Invest. 121, 4362-4371 10.1172/JCI46279
83. Minami, M., Shimizu, K., Okamoto, Y., Folco, E., Ilasaca, M.-L., Feinberg, M. W., Aikawa, M., and Libby, P. (2008) Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation J. Biol. Chem. 283, 9692-9703 10.1074/jbc.M709663200
84. Shi, J., Johansson, J., Woodling, N. S., Wang, Q., Montine, T. J., and Andreasson, K. (2010) The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity J. Immunol. 184, 7207-7218 10.4049/jimmunol.0903487
85. Kabashima, K. K., Saji, T. T., Murata, T. T., Nagamachi, M. M., Matsuoka, T. T., Segi, E. E., Tsuboi, K. K., Sugimoto, Y. Y., Kobayashi, T. T., Miyachi, Y. Y., Ichikawa, A. A., and Narumiya, S. S. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut J. Clin. Invest. 109, 883-893 10.1172/JCI0214459
86. Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., and Worley, P. F. (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids Neuron 11, 371-386 10.1016/0896-6273(93)90192-T
87. Melnikova, T., Savonenko, A., Wang, Q., Liang, X., Hand, T., Wu, L., Kaufmann, W. E., Vehmas, A., and Andreasson, K. I. (2006) Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern Neuroscience 141, 1149-1162 10.1016/j.neuroscience.2006.05.001
88. Lim, G. (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice Neurobiol. Aging 22, 983-991 10.1016/S0197-4580(01)00299-8
89. Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., Coppola, D., Morgan, D., and Gordon, M. N. (2002) Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice J. Neurosci. 22, 2246-2254
90. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., and Golde, T. E. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J. Clin. Invest. 112, 440-449 10.1172/JCI18162
91. Quinn, J., Montine, T., Morrow, J., Woodward, W. R., Kulhanek, D., and Eckenstein, F. (2003) Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease J. Neuroimmunol. 137, 32-41 10.1016/S0165-5728(03)00037-7
92. Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D., Trojanowski, J. Q., Lee, V. M.-Y., and Pratico, D. (2004) Modulation of Nuclear Factor-κB Activity by Indomethacin Influences Aβ Levels but Not Aβ Precursor Protein Metabolism in a Model of Alzheimer's Disease Am. J. Pathol. 165, 2197-2206 10.1016/S0002-9440(10)63269-5
93. Lanz, T. A., Fici, G. J., and Merchant, K. M. (2005) Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures J. Pharmacol. Exp. Ther. 312, 399-406 10.1124/jpet.104.073965
94. van Groen, T. and Kadish, I. (2005) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology Brain Res. Rev. 48, 370-378 10.1016/j.brainresrev.2004.12.026
95. Kukar, T., Prescott, S., Eriksen, J. L., Holloway, V., Murphy, M. P., Koo, E. H., Golde, T. E., and Nicolle, M. M. (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice BMC Neurosci. 8, 54 10.1186/1471-2202-8-54
96. McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., LaFerla, F. M., Jenkins, B. G., Kowall, N. W., and Dedeoglu, A. (2008) Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice Brain Res. 1207, 225-236 10.1016/j.brainres.2008.01.095
97. Carreras, I., McKee, A. C., Choi, J.-K., Aytan, N., Kowall, N. W., Jenkins, B. G., and Dedeoglu, A. (2013) R-flurbiprofen improves tau, but not Aβ pathology in a triple transgenic model of Alzheimer's disease Brain Res. 1541, 115-127 10.1016/j.brainres.2013.10.025
98. Choi, S.-H., Aid, S., Caracciolo, L., Minami, S. S., Niikura, T., Matsuoka, Y., Turner, R. S., Mattson, M. P., and Bosetti, F. (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease J. Neurochem. 124, 59-68 10.1111/jnc.12059
99. Subaiea, G. M., Adwan, L. I., Ahmed, A. H., Stevens, K. E., and Zawia, N. H. (2013) Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice Neurobiol. Aging 34, 2421-2430 10.1016/j.neurobiolaging.2013.04.002
100. Choi, J.-K., Carreras, I., Aytan, N., Jenkins-Sahlin, E., Dedeoglu, A., and Jenkins, B. G. (2014) The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging Brain Res. 1590, 85-96 10.1016/j.brainres.2014.09.067